JSMO Japanese Society of Medical Oncology

Contact USSearchen

SearchInput the word you want to find

  • HOME
  • ABOUT JSMO
  • 2024 Award Recipients

2024 Award Recipients

2024 Award Recipients

Annals of Oncology Award
Name Affiliation Affiliation
Kentaro Yamazaki Division of Gastrointestinal Oncology,
Shizuoka Cancer Center

Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial

https://www.sciencedirect.com/science/article/pii/S0923753420429837

Young Investigator Award
Name Affiliation Title
Keisuke Koroki Department of Gastroenterology,
Graduate School of Medicine, Chiba University
Phase Ib trial of durvalumab plus tremelimumab with particle therapy in HCC with macrovascular invasion: DEPARTURE trial
Tadayoshi Hashimoto Department of Gastroenterology and Gastrointestinal Oncology,
National Cancer Center Hospital East
The utility of circulating tumor DNA in gastrointestinal stromal tumor -a pooled analysis of SCRUM-Japan trials-
Daichi Fujimoto Internal Medicine III,
Wakayama Medical University
Prediction of prognosis in stage 4 lung cancer using machine learning:A multicenter cohort study (WJOG15121L:REAL-WIND)
Keiichiro Mori Department of Urology,
The Jikei University School of Medicine
Catalog of preoperative blood-based biomarkers in patients treated with radical cystectomy for bladder carcinoma
Kakuhiro Yamaguchi Hiroshima University Hospital,
Departement of Respiratory Medicine
Prospective observational study to identify a predictive blood marker for checkpoint inhibitor pneumonitis (CS-Lung 004)
Kyoko Yamaguchi Department of Hematology,
Oncology and Cardiovascular Medicine, Kyushu University Hospital
Efficacy of Pembrolizumab in metastatic colorectal cancer with TMB-High/non-MSI-high
Se Ik Kim Department of Obsetetrics and Gynecology,
Seoul National University College of Medicine
Predicting therapeutic response to PARP inhibitors in high-grade serous ovarian cancer: A Comprehensive proteomics study
Yung-Yeh Su National Institute of Cancer Research,
National Health Research Institutes, Tainan, Taiwan
Chemoradiation Augments Gemcitabine in HRD-Positive Pancreatic Cancer:
Results from A Randomized Adjuvant Trial
Wan-Ming Chen Graduate Institute of Business Administration,
College of Management,
Fu Jen Catholic University, Taipei, Taiwan
Effects of SGLT2 Inhibitors on Clinical Cancer Survival

※Titles omitted, listed in Japanese alphabetical order.

※Affiliations are listed as of the time of the award.

Scenes from the Award Ceremony

Scenes from the Award CeremonyScenes from the Award Ceremony

※Click to view a larger image.